Results 61 to 70 of about 14,464 (157)

A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer

Cancer Medicine, Volume 9, Issue 4, Page 1485-1494, February 2020., 2020
Mismatch repair proficient colorectal cancer has been refractory to single‐agent programmed cell death protein 1 inhibitor therapy. Colon GVAX is an allogeneic, whole‐cell, granulocyte‐macrophage colony‐stimulating factor‐secreting cellular immunotherapy that induces T‐cell immunity against tumor‐associated antigens and has previously been studied in ...
Mark Yarchoan, Chiung‐Yu Huang, Qingfeng Zhu, Anna K. Ferguson, Jennifer N. Durham, Robert A. Anders, Elizabeth D. Thompson, Noah S. Rozich, Dwayne L. Thomas II, Julie M. Nauroth, Christina Rodriguez, Arsen Osipov, Ana De Jesus‐Acosta, Dung T. Le, Adrian G. Murphy, Daniel Laheru, Ross C. Donehower, Elizabeth M. Jaffee, Lei Zheng, Nilofer S. Azad   +19 more
wiley   +1 more source

Comparison of the second-line treatments for patients with small cell lung cancer sensitive to previous platinum-based chemotherapy: A systematic review and Bayesian network analysis

Frontiers in Oncology, 2023
ObjectiveIt remains unclear what the best second-line treatment is for patients with small-cell lung cancer sensitive to previous platinum-based chemotherapy.MethodsWe systematically screened randomized controlled trials from several online databases ...
Hekai Shi, Nuojin Guo, Zeming Zhao, Ligang Liu, Tianyi Ni, Jinye Zhang, Yingjie Lu   +6 more
doaj   +1 more source

Drug-induced immune-mediated thrombocytopenia due to bevacizumab-FOLFOX therapy: a case report [PDF]

Kosin Medical Journal, 2023
Drug-induced immune thrombocytopenia (DITP) is a very rare disease, with an estimated annual incidence of 10 cases per million. Oxaliplatin and irinotecan are widely used as chemotherapy for high-risk stage II and III colorectal cancer, and DITP has been
Minna Kim, Jong Hoon Lee, Jong Yoon Lee
doaj   +1 more source

Ziv-aflibercept use in metastatic colorectal cancer.

J Adv Pract Oncol, 2013
Rodriguez M.
europepmc   +4 more sources

Safety of Intravitreal Injection of Biosimilar of Aflibercept in Rabbit Eyes

Journal of Ophthalmology, Volume 2020, Issue 1, 2020., 2020
Purpose. To assess the safety of biosimilar intravitreal aflibercept (CinnaGen Co., Iran) compared to the reference product (Eylea®; Bayer Schweiz AG, Zurich, Switzerland) in rabbit eyes through functional and histologic studies. Methods. Forty New Zealand albino rabbits were recruited to the study and were divided into four groups to be sacrificed at ...
Alireza Lashay, Hamid Riazi-Esfahani, Hooshang Faghihi, Ahmad Mirshahi, Hassan Khojasteh, Alireza Khodabande, Fahimeh Asadi Amoli, Fariba Ghassemi, Fatemeh Bazvand, Elias Khalili Pour, Nazanin Ebrahimiadib, Ali Torkashvand, Elham Delrish, Miguel Rechichi   +13 more
wiley   +1 more source

Intraocular Pharmacokinetics and Safety of Subretinal Injection Compared with Intravitreal Application of Conbercept in Vitrectomized Rabbit Eyes

Journal of Ophthalmology, Volume 2020, Issue 1, 2020., 2020
Purpose. To evaluate the ocular pharmacokinetic properties of subretinal conbercept injection in vitrectomized rabbit eyes and to compare them with those by intravitreal injection. Methods. The following groups of New Zealand white rabbits received conbercept injections (0.5 mg/0.05 ml): a subretinal group (subretinal injection in vitrectomized eyes ...
Teng-teng Yao, Xiao-liang Jin, Yuan Yang, Yi-xiao Wang, Ya-li Zhou, Fang-lin He, Zhao-yang Wang, Hamid Ahmadieh   +7 more
wiley   +1 more source

Viability of Primary Human Pigment Epithelium Cells and Muller-Glia Cells after Intravitreal Ziv-Aflibercept and Aflibercept [PDF]

, 2016
Purpose: The aim of this study was to access the safety profiles of 2 fusion proteins with anti-vascular endothelial growth factor action (ziv-aflibercept and aflibercept) on retinal pigment epithelium cells and Muller-Glia cells in culture by assessing ...
Haritoglou, Christos, Wolf, Armin, Eibl, Kirsten, Rodrigues, Eduardo Buchele, Farah, Michel Eid [UNIFESP], de Andrade, Gabriel Costa [UNIFESP], Costa de Andrade, G., Wertheimer, Christian, Eibl, Kirsten H., Haritoglou, Christos [UNIFESP], Farah, Michel Eid, Rodrigues, Eduardo Buchele [UNIFESP], Kampik, Anselm   +12 more
core   +1 more source

Real‐World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib

The Oncologist, Volume 25, Issue 1, Page e75-e84, January 2020., 2020
Abstract Background Trifluridine and tipiracil (FTD + TPI) and regorafenib (REG) are approved treatments for the treatment of refractory metastatic colorectal cancer (mCRC). This study assesses adherence and duration of therapy with FTD + TPI versus REG and explores the effect of sequencing on adherence. Materials and Methods Adults diagnosed with mCRC
Anuj K. Patel, Victoria Barghout, Mihran A. Yenikomshian, Guillaume Germain, Philippe Jacques, François Laliberté, Mei S. Duh   +6 more
wiley   +1 more source

CLINICAL AND ELECTROPHYSIOLOGICAL EVALUATION AFTER INTRAVITREAL ZIV-AFLIBERCEPT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION. [PDF]

Retina, 2017
Purpose: To evaluate the 6-month safety and efficacy of ziv-aflibercept intravitreal injections for treating exudative age-related macular degeneration.
de Oliveira Dias JR, de Andrade GC, Kniggendorf VF, Novais EA, Maia A, Meyer C, Watanabe SES, Farah ME, Rodrigues EB.   +8 more
europepmc   +2 more sources

Intravitreal Ziv-Aflibercept: Clinical Effects and Economic Impact

Asia-Pacific Journal of Ophthalmology, 2017
During the past decade, drugs that inhibit the actions of vascular endothelial growth factor (VEGF) have become standard-of-care treatment for a variety of chorioretinal vascular conditions. The off-label, intravitreal use of ziv-aflibercept (Zaltrap) has provided clinicians with an additional cost-effective drug.
Sumit Randhir, Singh, Avantika, Dogra, Michael, Stewart, Taraprasad, Das, Jay, Chhablani   +4 more
openaire   +2 more sources